source
- AstraZeneca's COPD drug cuts flare-ups in late-stage trials, offering new option for patientsIn two late-stage studies, an AstraZeneca therapy showed a statistically significant reduction in acute exacerbations that worsen chronic obstructive pulmonary disease. The data, released on Tuesda…
- Caspian Therapeutics launches with $50M to develop menin inhibitors for diabetes and cardiometabolic diseaseCaspian Therapeutics, a spin‑out from Kura Oncology, announced it is starting operations with $50 million in financing. The capital, led by BVF Partners and joined by Eli Lilly and Kura leadership,…